Greenwich LifeSciences, Inc.
GLSIGreenwich LifeSciences, Inc. (GLSI) is a biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company specializes in advancing innovative treatments, including vaccines designed to stimulate the immune system against specific tumor-associated antigens. Its pipeline primarily targets breast and other solid tumors.
Company News
Greenwich LifeSciences expanded its Phase III clinical trial FLAMINGO-01 to Austria, focusing on an immunotherapy to prevent breast cancer recurrences. The trial will include up to 150 global sites and aims to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients.
Although U.S. stocks closed mostly lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator ...
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
